Panacea Biotec is currently trading at Rs. 329.50, up by 3.50 points or 1.07% from its previous closing of Rs. 326.00 on the BSE.

The scrip opened at Rs. 320.90 and has touched a high and low of Rs. 330.90 and Rs. 314.35 respectively. So far 1817 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 581.00 on 15-May-2025 and a 52 week low of Rs. 293.10 on 30-Mar-2026.

Last one week high and low of the scrip stood at Rs. 337.75 and Rs. 314.35 respectively. The current market cap of the company is Rs. 1962.17 crore.

The promoters holding in the company stood at 72.48%, while Institutions and Non-Institutions held 3.21% and 24.31% respectively.

Panacea Biotec has received a Letter of Award (LoA) worth Rs 20.79 crore from Central Medical Services Society, Ministry of Health and Family Welfare, Government of India (CMSS). The company will supply Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP (Td Vaccine) in several tranches to CMSS starting from September / October 2026 till November / December 2028.

Panacea Biotec is a leading research-based Biotechnology Company with established research, manufacturing and marketing capabilities.